Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform

Background Antibody-based platforms (i.e., ADC) have emerged as one of the most encouraging tools for the cancer resistance caused by cancer stem cells (CSCs) enrichment. Our study might provide a promising therapeutic direction against drug resistance and serve as a potential precursor platform for...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Xiong Shu, Hui Wen Zhang, Shi Ya Liu, Li Xin Sun, Tao Zhang, Yu Liang Ran
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	PeerJ Inc. 2024-03-01
Saila:	PeerJ
Gaiak:	Antibody-based drug combination therapy Cancer stem cells Drug resistance ENO1 Oncotherapy
Sarrera elektronikoa:	https://peerj.com/articles/16817.pdf
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!